About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Laser Based Focal Ablation of Low Grade Prostate Cancer

NCT01192438·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Chicago

With

Visualase, Inc.

Age

45–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Male, 45 years of age or older
Diagnosis of prostate adenocarcinoma
Clinical stage T1c or T2a
Gleason score of 7 or less
A minimum of 12 biopsy cores sampled during diagnostic biopsy
Three or fewer biopsy cores with prostate cancer
No single biopsy core with greater than 50% of tumor involvement
A radiographically visible prostate lesion on MRI with concordance to biopsy sextant
A documented Karnofsky performance status of at least 70
Estimated survival of 20 years or greater, as determined by treating physician
Ability to give informed consent

You may not be if

Previous surgery, radiation, or androgen deprivation therapy for prostate cancer
Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI
History of previous pelvic radiation
Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater. (See Appendix A)
History of other primary non-skin malignancy within previous three years

The record

StatusCompleted

PhaseNo phase

Taking part9

StartedJan 2010

UpdatedMar 27, 2014

Conditions

Low Grade Prostate Cancer

Where1

University of Chicago
Chicago, Illinois, United States

Clareo Health | Laser Based Focal Ablation of Low Grade Prostate Cancer